Literature DB >> 9950297

A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine.

K M Wasan1, S M Cassidy, M Ramaswamy, A Kennedy, F W Strobel, S P Ng, T Y Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9950297     DOI： 10.1023/a:1011951602894

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  10 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

Review 2.  Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis.

Authors:  A D MBewu; P N Durrington
Journal:  Atherosclerosis       Date:  1990-11       Impact factor: 5.162

Review 3.  Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs.

Authors:  K M Wasan; S M Cassidy
Journal:  J Pharm Sci       Date:  1998-04       Impact factor: 3.534

Review 4.  Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs.

Authors:  K M Wasan
Journal:  J Pharmacol Toxicol Methods       Date:  1996-09       Impact factor: 1.950

5.  Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange.

Authors:  C Ouyang; E Choice; J Holland; M Meloche; T D Madden
Journal:  Transplantation       Date:  1995-11-15       Impact factor: 4.939

6.  Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A.

Authors:  A M Gardier; D Mathé; X Guédeney; J Barré; C Benvenutti; N Navarro; L Vernillet; D Loisance; J P Cachera; B Jacotot
Journal:  Ther Drug Monit       Date:  1993-08       Impact factor: 3.681

7.  Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Authors:  K M Wasan; P H Pritchard; M Ramaswamy; W Wong; E M Donnachie; L J Brunner
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

8.  Surface diffusion in human serum lipoproteins.

Authors:  R J Cushley; W D Treleaven; Y I Parmar; R S Chana; D B Fenske
Journal:  Biochem Biophys Res Commun       Date:  1987-08-14       Impact factor: 3.575

9.  Short-term effect of various doses of cyclosporin A on plasma lipoproteins and its distribution in blood: an experimental study.

Authors:  R J Andrade; M I Lucena; J A Gonzalez-Correa; C Garcia-Arias; P Gonzalez-Santos
Journal:  Hum Exp Toxicol       Date:  1993-03       Impact factor: 2.903

10.  Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins.

Authors:  S M Cassidy; F W Strobel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
  10 in total
  9 in total

1.  Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Authors:  K M Wasan; F W Strobel; S C Parrott; M Lynn; W J Christ; L D Hawkins; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

3.  The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins.

Authors:  D R Brocks; M Ramaswamy; A I MacInnes; K M Wasan
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

4.  Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.

Authors:  M Ramaswamy; K D Peteherych; A L Kennedy; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Rat and rabbit plasma distribution of free and chylomicron-associated BIRT 377, a novel small molecule antagonist of LFA-1-mediated cell adhesion.

Authors:  K M Wasan; M Ramaswamy; L Holtorf; A A Jayaraj; D J Hauss
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

6.  Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Authors:  Daniel P Rossignol; Kishor M Wasan; Eugene Choo; Edwin Yau; Nancy Wong; Jeffrey Rose; Jeffrey Moran; Melvyn Lynn
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Authors:  Kishor M Wasan; Olena Sivak; Richard A Cote; Aaron I MacInnes; Kathy D Boulanger; Melvyn Lynn; William J Christ; Lynn D Hawkins; Daniel P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Differences in the lipoprotein distribution of free and liposome-associated all-trans-retinoic acid in human, dog, and rat plasma are due to variations in lipoprotein lipid and protein content.

Authors:  K M Wasan; M Ramaswamy; S P Ng; W Wong; S C Parrott; J O Ojwang; T Wallace; P A Cossum
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

9.  Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.

Authors:  Kishor M Wasan; Verica Risovic; Olena Sivak; Stephen D Lee; Douglas X Mason; Gregory R Chiklis; Jim McShane; Melvyn Lynn; Nancy Wong; Daniel P Rossignol
Journal:  Pharm Res       Date:  2007-09-12       Impact factor: 4.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.